Andere Sprachen Seres Therapeutics, Inc.

Aktien

A14VXX

US81750R1023

MCRB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
0.5599 ^USD	-4.16%		-14.48%	-60.01%

09.04.	Seres Therapeutics gibt den Abschluss der Patientenrekrutierung für die klinische Phase 1B-Kohorte 2 der Studie SER-155 bei allogener HSCT bekannt	CI
06.03.	SERES THERAPEUTICS, INC. : Oppenheimer behält seine Kaufempfehlung bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09.04.
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT	09.04.
Declaration of Voting Results by Seres Therapeutics	08.04.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	28.03.
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	20.03.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19.03.
Seres Therapeutics Files a Definitive Proxy Statement with Securities and Exchange Commission	05.03.
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	05.03.
North American Morning Briefing : S&P 500 Futures -2-	05.03.
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024	28.02.
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference	27.02.
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz	26.02.
Seres Therapeutics, Inc. Announces Chief Financial Officer Changes	26.02.
Seres Therapeutics Appoints Marella Thorell as Executive Vice President	26.02.
Kenneth Steiner Submits a Shareholder Proposal to Seres Therapeutics	23.02.
SERES THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	18.01.
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	17.01.
SERES THERAPEUTICS ANNOUNCES VOWST COMMERCIAL LAUNCH UPDATE AND US FDA FAST TRACK DESIGNATION FOR SER-155	10.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Seres Therapeutics, Inc.

Aktien

A14VXX

US81750R1023

MCRB

Andere Sprachen

Filter